Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Impax Labs Inc (IPXL)

Impax Labs Inc (IPXL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,351,821
  • Shares Outstanding, K 73,870
  • Annual Sales, $ 775,790 K
  • Annual Income, $ -469,290 K
  • 60-Month Beta 1.15
  • Price/Sales 1.74
  • Price/Cash Flow 8.77
  • Price/Book 7.25
Trade IPXL with:
  • Price/Earnings ttm 29.05
  • Earnings Per Share ttm 0.63
  • Most Recent Earnings 0.11 on 03/01/18
  • Next Earnings Date 05/09/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/18
See More
  • Average Estimate 0.16
  • Number of Estimates 5
  • High Estimate 0.22
  • Low Estimate 0.11
  • Prior Year 0.11
  • Growth Rate Est. (year over year) +45.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.40 +5.17%
on 05/04/18
20.80 -12.02%
on 05/02/18
-1.45 (-7.34%)
since 04/04/18
3-Month
17.40 +5.17%
on 05/04/18
21.55 -15.08%
on 02/26/18
-1.10 (-5.67%)
since 02/02/18
52-Week
13.05 +40.23%
on 05/08/17
25.70 -28.79%
on 09/21/17
+5.10 (+38.64%)
since 05/04/17

Most Recent Stories

More News
Primidone Market Global Market Size, Share, Growth, Demand ,Trends and Forecast,2021 -2028 By Ameco Research

pune, India, Tue, 31 Aug 2021 01:38:27 / Comserve Inc. / -- The global Primidone market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other

IPXL : 18.30 (unch)
VRX.TO : 30.80 (-3.33%)
Parkinson’s Dyskinesia Market Research Report with Size, Share, Value, CAGR, Outlook, Analysis, Latest Updates, Data, and News 2020-2025

Parkinson's disease is a long term neurodegenerative disorder which affects the dopamine producing neurons in specific areas of the brain known as substantia nigra. This disease belongs to a group of conditions...

ACAD : 16.05 (+0.94%)
GSK : 39.09 (-0.33%)
IPXL : 18.30 (unch)
MRK : 72.19 (-0.85%)
NWPHF : 2.8000 (+0.36%)
NVS : 84.40 (-0.80%)
TEVA : 8.94 (-0.33%)
VRX.TO : 30.80 (-3.33%)
Primidone Market 2020 - Trends and Competitive Landscape Outlook Expand With Top Key Companies Till 2027 |Ameco Research

pune, India, Fri, 12 Mar 2021 05:48:17 / Comserve Inc. / -- Primidone Market (2020) Report provides Market Analysis on the basis of Market Trends, Product types, Major Applications, and Top Market Manufacturers...

IPXL : 18.30 (unch)
MFAC : 14.76 (-0.74%)
VRX.TO : 30.80 (-3.33%)
Global Parkinson's Disease Drugs Outlook to 2027, Featuring AbbVie Inc., Impax Laboratories Inc., Mylan NV, Orion Pharma and Pfizer Inc.

The "Parkinson's Disease Drugs - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

ABBV : 108.22 (+0.42%)
IPXL : 18.30 (unch)
Global Primidone Market 2020 Industry Size, Share, In-Depth Qualitative Insights, Growth Opportunity, Regional Analysis by 2025

The latest report entitled delivers on the industry- and economy-wide database for the business management that will offer development and profitability for players in this market. The report provides...

IPXL : 18.30 (unch)
VRX.TO : 30.80 (-3.33%)
Global ParkinsonOs Disease Drugs Market 2020 Key Players Data, Industry Analysis, Segmentation, Share, Size, Opportunities and Forecast to 2026

has published a new report to its repository titled as . There are comprehensive details on factors like driving factors, key improvements & challenges on which further development is dependent. The report...

GSK : 39.09 (-0.33%)
IPXL : 18.30 (unch)
MRK : 72.19 (-0.85%)
STDAF : 110.4200 (-3.98%)
TEVA : 8.94 (-0.33%)
VRX.TO : 30.80 (-3.33%)
Global Primidone Market 2020 Report Reviews on Key Manufacturers, Regional markets, Application and Segmentation by 2025

The report titled introduced by offers a whole study of the parent market, synopsis, new industry data, and innovative future tendencies, ruling vendors, and predictions, analysis. The report highlights...

IPXL : 18.30 (unch)
VRX.TO : 30.80 (-3.33%)
LifeMax Appoints Michael Huang, MD, as Chief Medical Officer

LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on developing first-in-class or best-in-class therapeutics for the treatment of orphan diseases with few or no therapeutic options, today...

AMGN : 217.80 (-0.15%)
IPXL : 18.30 (unch)
NVS : 84.40 (-0.80%)
LifeMax Receives Fast Track Designation For LM-030 for the Treatment of Netherton Syndrome

LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on developing first-in-class or best-in-class therapeutics for the treatment of orphan diseases that have few or no therapeutic options,...

IPXL : 18.30 (unch)
NVS : 84.40 (-0.80%)
LifeMax Launches AmMax Bio Following The License Of Worldwide Rights to a Clinical Stage Orphan Asset From Amgen

LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on treating orphan diseases that have few or no therapeutic options, today announced the formation of AmMax Bio, Inc. ("AmMax") and an...

AMGN : 217.80 (-0.15%)
IPXL : 18.30 (unch)

Business Summary

Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company engaged in the development, manufacture, and marketing of specialty prescription pharmaceutical products utilizing its own formulation expertise and drug delivery technologies. IMPAX Laboratories is focusing on two key areas,...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 19.77
1st Resistance Point 19.03
Last Price 18.30
1st Support Level 17.48
2nd Support Level 16.67
3rd Support Level N/A

See More

52-Week High 25.70
Fibonacci 61.8% 20.87
Fibonacci 50% 19.38
Last Price 18.30
Fibonacci 38.2% 17.88
52-Week Low 13.05

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar